Effectiveness and security of low-dose aspirin supplementation for patients before 12 weeks’ gestation: A systematic review

Abstract Purpose:The aim of the present study was to evaluate low-dose aspirin in the first trimester (≤12 weeks) whether or not can improve adverse pregnancy outcomes, such as pregnancy rate, live birth rate, pregnancy complications, and adverse reactions in pregnant women using a model‐based meta‐analysis.MethodsA systematic literature search of public databases was conducted. Entry criteria were randomized controlled trials evaluating the effect of aspirin administered at <12 weeks’ gestation compared to placebo or no-treatment. ResultsThe entry criteria were fulfilled by 22 randomized controlled trials on a combined total of 6173 participants. The main findings of this study were that for women with recurrent miscarriage, antiphospholipid antibodies, and IVF/ICSI treatment, the first trimester (<12 weeks) use of low dose aspirin for the pregnancy rate, fertility, pregnancy complications and aspirin adverse reactions had no significant effect. ConclusionsThis study demonstrated that the administration of low-dose aspirin at <12weeks’ gestation in high risk women does not change the pregnancy rate, the birth rate, the risk of pregnancy complications and aspirin adverse reactions.